Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/366
Full metadata record
DC FieldValueLanguage
dc.contributor.authorConnolly, Gregory C.-
dc.contributor.authorFrancis, Charles W.-
dc.date.accessioned2015-11-30T03:47:54Z-
dc.date.available2015-11-30T03:47:54Z-
dc.date.issued2013-
dc.identifier.urihttp://220.231.117.85:8000/handle/DHKTYTHD_123/366-
dc.description.abstractCancer-associated thrombosis accounts for almost one-fifth of all cases of venous thromboembolism (VTE) and is a leading cause of death, morbidity, delays in care, and increased costs. Our understanding of risk factors for cancer-associated thrombosis has expanded in recent years, and investigators have begun to use biomarkers and clinical prediction models to identify those cancer patients at greatest risk for VTE. The Khorana Risk Model, which is based on easily obtained biomarkers and clinical factors, has now been validated in several studies. Recent clinical trials of prophylaxis and treatment of VTE in cancer patients are reviewed here. In addition, consensus guidelines and expert opinion regarding management of VTE in specific challenging situations are presented.vi
dc.language.isoenvi
dc.publisherAmerican Society of Hematologyvi
dc.titleCancer-associated thrombosisvi
dc.typeArticlevi
Appears in CollectionsHuyết học = Hematology

Files in This Item:
File Description SizeFormat 
Hematology-2013-Connolly-684-91.pdf
  Restricted Access
171.55 kBAdobe PDFThumbnail
 Request Item


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.